Bilobalide

Bilobalide

SCHEMBL18327718

CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]23C(=O)O[C@@H]2OC(=O)C(O)[C@]213

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 1.00
▸ MEN1 O00255 2/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ THRB P10828 1/20 1.00
▸ ALOX15 P16050 1/20 1.00
▸ GLRA1 P23415 3/20 0.32
▸ GLRA2 P23416 3/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ GUSB P08236 1/20 0.32
▸ PTAFR P25105 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bilobalide SCHEMBL14029382 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL285824 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL13960090 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL29410789 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL19236272 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL16653675 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL29410808 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
Bilobalide SCHEMBL16452769 1.00 KMT2A (1.00) KMT2AMEN1SMN1; SMN2THRBALOX15
SCHEMBL29974351 0.84 MEN1 (0.72) KMT2AMEN1SMN1; SMN2THRBALOX15
SCHEMBL31364706 0.79 MEN1 (0.65) KMT2AMEN1SMN1; SMN2THRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180220656-A1 CONTROL OF PESTS IN MAIZE BY GINKGOLIDES AND BILOBALIDE BASF SE (DE) 2018-08-09 — — US disclosed
US-20180014544-A1 Method for Controlling Pests in Soybean BASF SE (DE) 2018-01-18 — — US disclosed
US-9801379-B2 Method for controlling pests in soybean BASF SE (DE) 2017-10-31 — — US disclosed
US-20170238554-A1 Method and Pesticidal Mixtures for Controlling Pentatomidae Pests BASF CORPORATION 2017-08-24 — — US disclosed
US-20170238554-A1 Method and Pesticidal Mixtures for Controlling Pentatomidae Pests BASF CORPORATION 2017-08-24 — — US disclosed
WO-2017032580-A1 CONTROL OF PESTS IN COTTON BY GINKGOLIDES AND BILOBALIDES BASF SE (DE) 2017-03-02 — — WO disclosed
WO-2017025454-A1 CONTROL OF PESTS IN MAIZE BY GINKGOLIDES AND BILOBALIDE BASF SE (DE) 2017-02-16 — — WO disclosed
US-20160366889-A1 Method for Controlling Pests in Soybean BASF SE (DE) 2016-12-22 — — US disclosed
US-20160366889-A1 Method for Controlling Pests in Soybean BASF SE (DE) 2016-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160366889-A1 Method for Controlling Pests in Soybean GAK, DGKG, AGL KMT2A 2845/4885MEN1 2443/4885SMN1; SMN2 2944/4885
US-20180014544-A1 Method for Controlling Pests in Soybean GAK, DGKG, GRK6 KMT2A 3043/4885MEN1 2041/4885SMN1; SMN2 2677/4885
US-20180220656-A1 CONTROL OF PESTS IN MAIZE BY GINKGOLIDES AND BILOBALIDE GAK, AGL, BROX KMT2A 1781/4885MEN1 475/4885SMN1; SMN2 4259/4885
US-20170238554-A1 Method and Pesticidal Mixtures for Controlling Pentatomidae Pests CASP9, CASP6, CASP14 KMT2A 3269/4885MEN1 1446/4885SMN1; SMN2 3780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback